The Fas signalling pathway and its role in the pathogenesis of cancer
- 1 August 2004
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 4 (4) , 321-326
- https://doi.org/10.1016/j.coph.2004.03.008
Abstract
No abstract availableKeywords
Funding Information
- Higher Education Authority
- Science Foundation Ireland
- Wellcome Trust
- Enterprise Ireland
This publication has 44 references indexed in Scilit:
- Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cellsOncogene, 2003
- FAP-1 Association with Fas (Apo-1) Inhibits Fas Expression on the Cell SurfaceMolecular and Cellular Biology, 2003
- Human Urinary Bladder Transitional Cell Carcinomas Acquire the Functional Fas Ligand during Tumor ProgressionThe American Journal of Pathology, 2003
- Death and anti-death: tumour resistance to apoptosisNature Reviews Cancer, 2002
- Fas ligand is up-regulated during the colorectal adenoma–carcinoma sequenceEuropean Journal of Surgical Oncology, 2002
- Promotion of Activated Human B Cell Apoptosis and Inhibition of Ig Production by Soluble CD95 Ligand: CD95-Based Downregulation of Ig Production Need Not Culminate in Activated B Cell DeathCellular Immunology, 2000
- The Hallmarks of CancerCell, 2000
- Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in MiceScience, 1996
- Fas Ligand-Induced Apoptosis as a Mechanism of Immune PrivilegeScience, 1995
- A role for CD95 ligand in preventing graft rejectionNature, 1995